Lite Strategy, Inc.
LITS Healthcare Biotechnology
Lite Strategy, Inc.’s revenue for fiscal 2024 (year ended June 2024) was $65.3 million, up 33.8% from fiscal 2023. In the quarter to June 2026, EPS fell 11.0% and free cash flow grew 179.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow LITS
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Gross Profit |
+8 more TTM periods Free account |
— | — | — | — |
R&D Expenses |
0.77 | 0.51 | 0.17 | 0.12 | |
SG&A Expenses |
11.44 | 11.60 | 11.93 | 12.05 | |
Operating Income |
(12.84) | (39.26) | (58.09) | (66.58) | |
Non-operating Income/Expense |
1.27 | (0.44) | (2.73) | (4.57) | |
| (11.58) | (39.70) | (60.82) | (71.15) | ||
Income after Tax |
(11.58) | (39.70) | (60.82) | (71.15) | |
Dividends (Preferred) |
— | — | 0.00 | — | |
Net Income Common |
(11.58) | (39.70) | (60.82) | (71.15) | |
EPS (Basic) |
(1.31) | (1.73) | (2.00) | (2.05) | |
EPS (Diluted) |
(1.31) | (1.73) | (2.00) | (2.05) | |
Shares (Basic, Weighted) |
12.37 | 20.04 | 27.31 | 34.28 | |
Shares (Diluted, Weighted) |
12.37 | 20.04 | 27.31 | 34.28 | |
EBIT Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
EBT margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
EBITDA |
(12.84) | (39.26) | (58.09) | (66.58) | |
EBIT |
(12.84) | (39.26) | (58.09) | (66.58) | |
EPS (Diluted, from Cont. Ops) |
(1.31) | (1.74) | (2.01) | (2.06) | |
EPS (Diluted, Consolidated) |
(1.31) | (1.74) | (2.01) | (2.06) | |
EPS (Basic, Consolidated) |
(1.31) | (1.74) | (2.01) | (2.06) | |
Shares (Diluted, Average) |
12.37 | 20.04 | 27.31 | — | |
EPS (Basic, from Continuous Ops) |
(1.31) | (1.74) | (2.01) | (2.06) | |
Income from Continuous Operations |
(11.58) | (39.70) | (60.82) | (71.15) | |
Consolidated Net Income/Loss |
(11.58) | (39.70) | (60.82) | (71.15) | |
EBITDA Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating Cash Flow Margin |
0.00% | 0.00% | 0.00% | 0.00% |